Hubei Cancer Hospital ( Site 1329)

Wuhan, Hubei 430079

0 studies enrolling now · 1 studies all time

What they study most

Prostatic Neoplasms

Studies at this site

• Study of Pembrolizumab (MK-3475) Plus Docetaxel Versus Placebo Plus Docetaxel in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC) (MK-3475-921/KEYNOTE-921) — Completed